Post

New research · Hematology
Oncology research and treatment · 1d
Systematic reviewOncology research and treatment · 2026

Efficacy and Safety of Prophylactic Tocilizumab in Patients with Multiple Myeloma Receiving Bispecific Antibodies: A Systematic Review and Meta-Analysis.

Angeline Tancherla, Fernando Dharmaraja, Andree Kurniawan
Read paper
HematologySystematic review

Prophylactic tocilizumab is associated with lower all-grade cytokine release syndrome.

Efficacy and Safety of Prophylactic Tocilizumab in Patients with Multiple Myeloma Receiving Bispecific Antibodies: A Systematic Review and Meta-Analysis.

Angeline Tancherla et al. · Oncology research and treatment · 2026
Background

Cytokine release syndrome (CRS) remains a major toxicity associated with bispecific antibody (BsAb) therapy in relapsed/refractory multiple myeloma (RRMM).

Methods

Databases were searched for studies evaluating prophylactic tocilizumab in patients with RRMM receiving BsAb therapy.

n = 704 patients
Results

preventive tocilizumab is linked to a much lower risk of cytokine release syndrome

RR by subgroup · 95% CI
null = 1
all-grade CRS incidence
0.29
although this did not reach statistical
0.22
More results

A pooled analysis of two studies evaluating grade ≥2 CRS showed a numerically lower risk with prophylaxis, although this did not reach statistical significance (RR 0.22, 95% CI 0.02-2.57; p = 0.23).

CRS events were predominantly low grade, short-lived, and occurred during step-up dosing.

More results

ICANS was uncommon, and infection and hematologic toxicity rates were comparable between groups.

No signal of reduced overall response rate was observed (RR 1.21, 95% CI 0.91-1.62; p = 0.19).

“
Conclusion · 1 of 2

Prophylactic tocilizumab is associated with lower CRS incidence without compromising efficacy in RRMM patients receiving BsAb therapy.

Conclusion · 2 of 2

Prospective randomized studies are warranted to confirm these findings and refine prophylactic strategies.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
30% higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Cohort Study
49%
Nearly half of patients had problems 30 days after spleen removal for blood cancer
Cohort Study
OR 3.95
flexible sigmoidoscopy makes it almost 4 times more likely to find gastrointestinal GvHD
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.
Guideline
“By integrating international evidence with local circumstances, this document aims to provide Korean clinicians with practical, upto-date guidance to enhance the routine care of patients with TTP.”